These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8772681

  • 1. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
    Mark DB, Talley JD, Topol EJ, Bowman L, Lam LC, Anderson KM, Jollis JG, Cleman MW, Lee KL, Aversano T, Untereker WJ, Davidson-Ray L, Califf RM.
    Circulation; 1996 Aug 15; 94(4):629-35. PubMed ID: 8772681
    [Abstract] [Full Text] [Related]

  • 2. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ, Satler LF.
    J Invasive Cardiol; 1994 Aug 15; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [Abstract] [Full Text] [Related]

  • 3. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ.
    Am J Cardiol; 1998 Jul 01; 82(1):7-12. PubMed ID: 9671000
    [Abstract] [Full Text] [Related]

  • 4. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
    JAMA; 1997 Aug 13; 278(6):479-84. PubMed ID: 9256222
    [Abstract] [Full Text] [Related]

  • 5. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ.
    Am J Cardiol; 1996 May 15; 77(12):1045-51. PubMed ID: 8644655
    [Abstract] [Full Text] [Related]

  • 6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators.
    N Engl J Med; 1994 Apr 07; 330(14):956-61. PubMed ID: 8121459
    [Abstract] [Full Text] [Related]

  • 7. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ.
    J Am Coll Cardiol; 1997 Jul 07; 30(1):149-56. PubMed ID: 9207636
    [Abstract] [Full Text] [Related]

  • 8. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Jul 07; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 9. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K, Kamat SG, Schafer AI, Bañez EI, Jordan R, Kleiman NS, Hellums JD.
    Circulation; 1995 Mar 01; 91(5):1427-31. PubMed ID: 7867183
    [Abstract] [Full Text] [Related]

  • 10. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
    Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M.
    Lancet; 1994 Apr 09; 343(8902):881-6. PubMed ID: 7908357
    [Abstract] [Full Text] [Related]

  • 11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr 09; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ.
    Circulation; 2000 Dec 12; 102(24):2923-9. PubMed ID: 11113041
    [Abstract] [Full Text] [Related]

  • 17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG InvestigatorsDepartment of Cardiology, Cleveland Clinic Foundation, OH 44195, USA..
    N Engl J Med; 1997 Jun 12; 336(24):1689-96. PubMed ID: 9182212
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
    Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ.
    Circulation; 1994 Oct 12; 90(4):1757-64. PubMed ID: 7923659
    [Abstract] [Full Text] [Related]

  • 19. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr 12; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 20. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
    Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM.
    J Am Coll Cardiol; 1998 Aug 12; 32(2):311-9. PubMed ID: 9708455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.